Medication

ApprovedSmall molecule

NNYU Langone Health

Medication is one of 457 small molecule programs targeting Pemphigus Vulgaris. It is currently in Approved.

Indications

Total Trials

Active Trials

456

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pemphigus VulgarisActive, not recruiting

Low Back PainActive, not recruiting

Mitral RegurgitationActive, not recruiting

HypothyroidismActive, not recruiting

IschemiaActive, not recruiting

Chronic ProstatitisActive, not recruiting

Peripheral Arterial DiseaseActive, not recruiting

AnxietyActive, not recruiting

Patent Foramen OvaleActive, not recruiting

Postherpetic NeuralgiaActive, not recruiting

Pemphigus VulgarisPreclinical

Active, not recruiting

Low Back PainPreclinical

Active, not recruiting

Mitral RegurgitationPreclinical

Active, not recruiting

HypothyroidismPreclinical

Active, not recruiting

IschemiaPreclinical

Active, not recruiting

Chronic ProstatitisPreclinical

Active, not recruiting

Peripheral Arterial DiseasePreclinical

Active, not recruiting

AnxietyPreclinical

Active, not recruiting

Patent Foramen OvalePreclinical

Active, not recruiting

Postherpetic NeuralgiaPreclinical

Active, not recruiting

Showing 10 of 16 indications

Competition

Competitive Landscape

540 competitors in Chronic Kidney Disease

#DrugCompanyPhaseTrials

Medication

NNYU Langone Health

Approved

1 2

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

16 3

Uloric

Takeda

Preclinical

3 4

Glucotrol

Pfizer

Preclinical

1 5

Lorelco

Sanofi

Preclinical

1 6

Activase

Flomax

Miochol

BBausch Health Americas, Inc.

Preclinical

2 9

Epoetin Beta

Roche

Preclinical

5 10

Genotropin

EMD Serono

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

N/ANot yet recruiting

Large Vessel Occlusion

NCT06702657

Q2 2028

N/ARecruiting

Mitral Regurgitation

NCT06883864

N/ARecruiting

Prevention

NCT06693934

Q4 2028

Not yet recruiting

Low Back Pain

NCT06967363

Q4 2029

PreclinicalRecruiting

Atrial Fibrillation

NCT06299514

Clinical

Trials by Indication[1]

Ischemia2 trials

ISCHEMIA-EXTEND (Extended Follow-up)

Active, not recruiting·NNYU Langone Health··NCT04894877·5,391 enrolled

International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)

Completed·NNYU Langone Health·N/A·NCT01471522·5,179 enrolled

Low back pain1 trial

Multimodal Imaging and Biospecimen Collection for Low Back Pain (LBPB)

Not yet recruiting·PPeking University Third Hospital··NCT06967363·360 enrolled

Anxiety1 trial

Brief Group Psychotherapy for Anxiety and Depression

Completed·—·N/A·NCT04489641·100 enrolled

Mitral regurgitation1 trial

Efficacy and Safety of Catheter abLation in patiEnts With seVere mitrAl regurgiTation and pErsistent Atrial Fibrillation: a Randomized Controlled Trial

Recruiting·—·N/A·NCT06883864·146 enrolled

Chronic Kidney Disease1 trial

ISCHEMIA-Chronic Kidney Disease Trial

Completed·NNYU Langone Health·Phase 4·NCT01985360·777 enrolled

15 more indications

Peripheral Arterial Disease1 trial

Pulsed Electromagnetic Field Versus Treadmill Walking in Peripheral Arterial Disease

Unknown status·—·N/A·NCT04621097·70 enrolled

Cystitis1 trial

Efficacy of Low-Intensity Shockwave Therapy in Treating Radiation Cystitis

Enrolling by invitation·TThanakrit Visuthikosol·Phase 1·NCT07016451·40 enrolled

Chronic Prostatitis1 trial

Risk Factors for Chronic Prostatitis Patients in Northwest China

Recruiting·SShaanxi Provincial People's Hospital··NCT06385977·400 enrolled

Prevention1 trial

Jockey Club Precision Prevention Programme on Young Onset Diabetes

Recruiting·JJuliana CN Chan·N/A·NCT06693934·9,000 enrolled

Low Anterior Resection Syndrome1 trial

Effect of Treatment of Low Anterior Resection Syndrome After Rectal Cancer Surgery

Completed·MMirna Abraham-Nordling·N/A·NCT03215017·45 enrolled

Pemphigus Vulgaris1 trial

Low-level Laser Therapy on Oral Pemphigus Vulgaris Patients.

Not yet recruiting·—·N/A·NCT06971172·22 enrolled

Large Vessel Occlusion1 trial

A Randomized Clinical Trial on Urgent Angioplasty for IntraCranial Atherosclerotic Stenosis-related Large-Vessel Occlusion After Mechanical Thrombectomy

Not yet recruiting·—·N/A·NCT06702657·612 enrolled

Postherpetic Neuralgia1 trial

Electroacupuncture Therapy for Treating Postherpetic Neuralgia

Completed·TThe Third Affiliated hospital of Zhejiang Chinese Medical University·N/A·NCT04594226·132 enrolled

Patent foramen ovale1 trial

SENIOR: Stroke Prevention in the Elderly by Patent Foramen Ovale closuRe vs Anticoagulation

Recruiting·TTaichung Veterans General Hospital··NCT07479147·400 enrolled

Hypothyroidism1 trial

Comparison of Aerobic and Resistance Training on Exercise Capacity, Depression and Quality of Life in Hypothyroidism.

Recruiting·RRiphah International University·N/A·NCT06377826·66 enrolled

Major Depressive Disorder1 trial

The Study of Mindfulness-based Cognitive Therapy and Major Depressive Disorder

Unknown status·SShanghai Mental Health Center·N/A·NCT03558256·105 enrolled

Diabetic Neuropathy1 trial

Effect of Physical Activity on Neurogenesis in Peripheral Diabetic Neuropathy Type-II Diabetes

Unknown status·HHealth Education Research Foundation (HERF)·N/A·NCT06101368·44 enrolled

Microvascular Dysfunction1 trial

Comprehensive Treatment of Angina in Women With Microvascular Dysfunction

Completed·—·N/A·NCT02910154·62 enrolled

Renal Cell Carcinoma1 trial

Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma

Unknown status·HHerlev and Gentofte Hospital·Phase 2·NCT04644432·30 enrolled

Atrial Fibrillation1 trial

Resynchronization for Ambulatory Heart Failure Trial in Patients With Chronic Atrial Fibrillation - Pharmacological Rate Control vs. Pace and Ablate With Conduction System Pacing

Recruiting·HHabib Khan·Preclinical·NCT06299514·600 enrolled

Sources

References

[1]
ClinicalTrials.gov — 21 trial records for Medication. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Medication compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Medication. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NYU Langone Health company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: NNYU Langone Health

Medication

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q2 2028

Q4 2028

Q4 2029

Trials by Indication[1]

Ischemia2 trials

Low back pain1 trial

Anxiety1 trial

Mitral regurgitation1 trial

Chronic Kidney Disease1 trial

Peripheral Arterial Disease1 trial

Cystitis1 trial

Chronic Prostatitis1 trial

Prevention1 trial

Low Anterior Resection Syndrome1 trial

Pemphigus Vulgaris1 trial

Large Vessel Occlusion1 trial

Postherpetic Neuralgia1 trial

Patent foramen ovale1 trial

Hypothyroidism1 trial

Major Depressive Disorder1 trial

Diabetic Neuropathy1 trial

Microvascular Dysfunction1 trial

Renal Cell Carcinoma1 trial

Atrial Fibrillation1 trial

References

Drug Info

Quick Facts

Related News